Issued 2026-08-13 at $1.80 · now $1.79 (2026-08-13, −0.6% since)
Based on its own history, a month from the 2026-08-13 close, ANVS has typically landed between $1.19 and $2.91 — a range of −33.8% to +61.6% from the issuance price $1.80.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,618 overlapping 1 month windows · 2020-01-29 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($1.80) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where ANVS has typically landed a month from the 2026-08-13 close of $1.8 — the range is history, not a prediction.
- now $1.79 (-0.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.68 (-6.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.44–$1.91
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.19–$2.91
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2021-07-12 | −68.2% | −70.6% | +3.2% |
| 2021-07-27 | −67.9% | −69.3% | +0.0% |
| 2021-07-23 | −67.1% | −71.1% | +0.0% |
| 3 best | |||
| 2021-05-14 | +293.9% | +0.0% | +293.9% |
| 2021-05-13 | +270.7% | +0.0% | +290.9% |
| 2021-05-18 | +257.5% | +0.0% | +265.0% |
1,618 overlapping windows · 2020-01-29 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2027 — Trial primary completion: Phase 3 primary completion: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD (source, as of 2026-08-14)
- September 2029 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Study of Buntanetap in Participants With PD (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.